ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Boston Consulting Group (BCG) and OpenAI today announced a multiyear expansion of their partnership with Frontier Alliance to continue to help organizations move beyond experimentation and accelerate ...
(Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its ...
OpenAI’s new Frontier Alliances with Accenture, BCG, Capgemini, and McKinsey aim to speed enterprise agent deployments and AI strategy work.
Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Intravesical immunotherapy in the form of BCG is the only effective adjuvant therapy for high-risk NMIBC (non-muscle-invasive bladder cancer) that reduces progression of disease Response to salvage ...
The SWOG S1602 trial ( NCT03091660) evaluated the noninferiority of the Tokyo versus TICE BCG strains, as well as testing the superiority of T cell priming with intradermal BC before intravesical ...
The MarketWatch News Department was not involved in the creation of this content. -- Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results